AtaiBeckley (ATAI) Income from Continuing Operations (2020 - 2026)

AtaiBeckley (ATAI) recorded quarterly Income from Continuing Operations of 29982000.0 in Q1 2026, down 13.29% quarter-over-quarter from 26465000.0 in Q1 2025, and down 13.29% on a YoY basis from 34577027.63 in Q1 2025.

AtaiBeckley (ATAI) Income from Continuing Operations (2020 - 2026) Analysis & Trends

AtaiBeckley has disclosed Income from Continuing Operations across 6 years of filings, most recently posting 61098000.0 for Q3 2025.

  • Income from Continuing Operations for Q3 2025 came in at 61098000.0, down 132.44% year-over-year; the trailing twelve-month figure through Sep 2025 was 154656000.0 (down 22.88% YoY), and the FY2024 annual result was 148761000.0, down 288.71% from the prior year.
  • Income from Continuing Operations was 29982000.0 for Q1 2026 at AtaiBeckley, down from 26465000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 26465000.0 in Q1 2025 to a low of 29982000.0 in Q1 2026.
  • The 5-year median for Income from Continuing Operations is 31858000.0 (2023), against an average of 30744684.21.
  • Across the five-year window, Income from Continuing Operations plunged 842.61% in 2021 and jumped 231.08% in 2023, its largest moves.
  • AtaiBeckley's Income from Continuing Operations stood at 52136000.0 in 2021, then gained by 13.07% to 45323000.0 in 2022, then jumped by 63.12% to 16716000.0 in 2023, then tumbled by 135.34% to 39340000.0 in 2024, then tumbled by 55.31% to 61098000.0 in 2025.
  • The last three Income from Continuing Operations figures came in at 61098000.0 (Q3 2025), 27753000.0 (Q2 2025), and 26465000.0 (Q1 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -26.94 Mn
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -2.97 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 30.80 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -3.40 Mn
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -14.46 Mn
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -1.50 Mn
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 1.03 Bn
9 Abivax 91.96 Bn 91.96 Bn - -56.48 Mn
10 AtaiBeckley 1.45 Bn 1.45 Bn - -29.98 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -29.98 Mn
Sep 30, 2025 -61.10 Mn
Jun 30, 2025 -27.75 Mn
Mar 31, 2025 -26.47 Mn
Mar 31, 2025 -26.47 Mn
Dec 31, 2024 -39.34 Mn
Sep 30, 2024 -26.29 Mn
Jun 30, 2024 -57.18 Mn
Mar 31, 2024 -25.68 Mn
Dec 31, 2023 -16.72 Mn
Sep 30, 2023 43.61 Mn
Jun 30, 2023 -31.86 Mn
Mar 31, 2023 -33.36 Mn
Dec 31, 2022 -45.32 Mn
Sep 30, 2022 -33.27 Mn
Jun 30, 2022 -30.86 Mn
Mar 31, 2022 -31.96 Mn
Dec 31, 2021 -52.14 Mn
Sep 30, 2021 -26.87 Mn
Jun 30, 2021 -67.36 Mn